Ravandi, Farhad

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 664

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology

Acute Myeloid Leukemia ResearchMultiple and Secondary Primary Cancers

Cited by 399

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 330

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 325

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research

Acute Myeloid Leukemia ResearchCell death mechanisms and regulation

Cited by 192

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 161

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 133

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Ravandi, F., Kantarjian, H., Faderl, S., Garcia-Manero, G., O’Brien, S., Koller, C., Pierce, S., Brandt, M., Kennedy, D., Cortes, J., et al. (2010) · Leukemia Research

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 125

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 120

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., et al. (2017) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 112

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer

Acute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors Research

Cited by 104

Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Sasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 101

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Ravandi, F., Gojo, I., Patnaik, M. M., Minden, M. D., Kantarjian, H., Johnson-Levonas, A. O., Fancourt, C., Lam, R., Jones, M. B., Knox, C. D., et al. (2016) · Leukemia Research

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 57

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 55

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

Chihara, D., Masarova, L., Newberry, K. J., Maeng, H., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Cortes, J., Kantarjian, H., & Verstovsek, S. (2016) · Leukemia Research

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 21

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data

Jain, P., Kantarjian, H., Estey, E., Pierce, S., Cortes, J., Lopez-Berestein, G., & Ravandi, F. (2014) · Clinical Lymphoma Myeloma and Leukemia

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 15